Bio-Techne Shareholders Approve Merck KGaA Acquisition

Bio-Techne shareholders have approved the company's acquisition by Merck KGaA after the US antitrust waiting period expired.

This development moves the deal closer to completion and sets the stage for Bio-Techne's integration into Merck KGaA's portfolio of life science products.

Bio-Techne operates through two segments: Protein Sciences, which supplies research reagents, and Diagnostics and Genomics, which includes molecular diagnostics and spatial biology tools.

The company has faced softer demand from biotechnology customers and cuts to academic research funding in the US, but with shareholder approval secured, the focus is now on closing conditions.